698 Stock Overview
A biopharmaceutical company, develops precision T cell therapies to treat solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$1.43 |
| 52 Week Low | US$0.67 |
| Beta | 1.24 |
| 1 Month Change | 11.81% |
| 3 Month Change | -5.29% |
| 1 Year Change | -11.54% |
| 3 Year Change | -92.41% |
| 5 Year Change | n/a |
| Change since IPO | -92.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 698 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.5% | 0.4% | 0.6% |
| 1Y | -11.5% | -23.7% | 5.4% |
Return vs Industry: 698 exceeded the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: 698 underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| 698 volatility | |
|---|---|
| 698 Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 698's share price has been volatile over the past 3 months.
Volatility Over Time: 698's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Achilles Therapeutics plc Fundamentals Summary
| 698 fundamental statistics | |
|---|---|
| Market cap | €34.58m |
| Earnings (TTM) | -€59.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 698 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 698 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.43m |
| Earnings | -US$64.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 698 perform over the long term?
See historical performance and comparison